Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer, endometriosis primary and secondary amenorrhea, menopause and hormone replacement therapy with oestrogen. 150mg injection used as progesterone-only contraceptive
Tablets: Secondary amenorrhea: abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer: 5-10mg daily from 16th-21st day of the cycle for 5-10 days. Endometriosis: 10mg TID from day one of the cycle for 90 days. Primary and secondary amenorrhoea: 5-10mg daily for 10 days. Menopause: 10mg-20mg daily continuously. Hormone replacement therapy with oestrogen: 5-10mg daily from 16th - 21st day of estrogen therapy. Sterile Aqueous Suspension: Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. Contraceptive Injection: Medroxyprogesterone acetate contraceptive injection is indicated only for the prevention of pregnancy. It is administered at 3-month [13-week] intervals -150mg.
Hypersensitivity reactions; changes in libido; acne; GI disturbances; weight gain; breakthrough bleeding; breast changes; mental depression; and fluid retention.
Store as labelled. Keep out of reach of children.